Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ETX-101 by Encoded Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
ETX-101 is under clinical development by Encoded Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of...